EP3113778
Pýridasín afleiður til notkunar við að fyrirbyggja eða meðhöndla slingursjúkdóm
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
6.3.2015EP published:
6.6.2018EP application number:
15709324.6
EP translation filed:
27.8.2018Grant published:
15.9.2018EPO information:
European Patent Register
Max expiry date:
5.3.2035Expiry date:
5.3.2023
Title:
PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER
Timeline
Today
6.3.2015EP application
6.6.2018EP Publication
27.8.2018Translation submitted
15.9.2018Registration published
5.3.2023Expires
Owner
Name:
Takeda Pharmaceutical Company LimitedAddress:
1-1 Doshomachi 4-chome Chuo-ku, 541-0045, Osaka-shi, Osaka, JP
Inventor
Name:
ALMOND, SarahAddress:
Cambridge CB4 0PZ, GB
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201403944Date:
6.3.2014Country:
GB
Classification
Categories:
A61K 31/501, A61P 25/00, A61P 25/14
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 12.3.2019
Expires: 5.3.2020
Payer: Tego ehf.
Number: 6
Paid: 11.9.2020
Expires: 5.3.2021
Payer: Tego ehf.
Number: 7
Paid: 18.2.2021
Expires: 5.3.2022
Payer: Sigurjónsson & Thor ehf.
Number: 8
Paid: 18.2.2022
Expires: 5.3.2023
Payer: Patice ehf.